Several common HLA-DR types share largely overlapping peptide binding repertoires

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3363-3373

  Southwood, Scott ^a   Sidney, John ^a   Kondo, Akihiro ^b   Del Guercio, Marie France ^a   Appella, Ettore ^c   Hoffman, Stephen ^d   Kubo, Ralph T ^d   Chesnut, Robert W ^a   Grey, Howard M ^a   Sette, Alessandro ^a  

^a Epimmune   (United States)

^b National Institutes of Health ^*

^c NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^d CYTEL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; GENETIC POLYMORPHISM; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ALGORITHMS; ALLELES; AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TRANSFORMED; DATABASES, FACTUAL; EPITOPES; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING;

EID: 0032055915     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Fitch, F. W., D. W. Lancki, and T. F. Gajewski. 1993. T-cell-mediated immune regulation: help and suppression. In Fundamental Immunology, W. E. Paul, ed. Raven Press Ltd., New York, p. 773.
2. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
3. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.
4. + T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:741.
5. Diepolder, H. M., R. Zachoval, R. M. Hoffman, E. A. Wieranga, T. Santantnio, M. C. Jung, D. Eichenlaub, and G. R. Pape. 1995. Possible mechanisms involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006.
6. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29.
7. - T cells and is restricted to the DR region of the MHC complex. J. Immunol. 140:3610.
8. Cease, K. B., and J. A. Berzofsky. 1994. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu. Rev. Immunol. 12: 923.
9. Hahn, S., R. Gehri, and P. Erb. 1995. Mechanism and biological significance of CD4 mediated cytotoxicity. Immunol. Rev. 146:57.
10. Yamamura, M. K., K. Uyemura, R. J. Deans, K. Weinberg, T. H. Rea, B. R. Bloom, and R. L. Modlin. 1991. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277.
11. Kaufmann, S. H. E. 1993. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11:129.
12. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12:227.
13. + subset expression in murine candidiasis: Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J. Immunol. 150:925.
14. + T cell and IFN-γ-dependent elimination of infected hepatocytes. J. Immunol. 157:4061.
15. Hunt, D. F., H. Michel, T. A. Dickinson, J. Shabanowitz, A. L. Cox, K. Sakaguchi, and E. Appella. 1992. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256:1817.
16. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
17. Rudensky, A. Y., P. Preston-Hurlburt, S-C. Hong, A. Barlow, and C. A. Janeway. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622.
18. Chicz, R. M., R. G. Urban, W. S. Lane, J. C. Gorga, L. J. Stern, D. A. A. Vignali, and J. L. Strominger. 1992. Predominant naturally processed peptides bound to HLA DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764.
19. Madden, D. R. 1995. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13:587.
20. Fremont, D. H., W. A. Hendrickson, P. Marrack, and J. Kappler. 1996. Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001.
21. Rothbard, J. B., R. I. Lechler, K. Howland, D. Bal, D. D. Eckels, R. Sekaly, E. O. Long, W. R. Taylor, and J. R. Lamb. 1988. Structural model of HLA-DR1 restricted T cell antigen recognition. Cell 52:515.
22. Krieger, J. I., R. W. Karr, H. M. Grey, W-Y. Yu, D. O'Sullivan, L. Batovsky, Z-L. Zheng, S. M. Colon, F. C. A. Gaeta, J. Sidney, M. Albertson, M-F. del Guercio, R. W. Chesnut, and A. Sette. 1991. Single amino acid changes in DR and antigen define residues critical for peptide-binding and T cell recognition. J. Immunol. 146:2331.
23. Jardetzky, T. S., J. C. Gorga, R. Busch, J. Rothbard, J. L. Strominger, and D. C. Wiley. 1990. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797.
24. Sette, A., S. Buus, E. Appella, J. A. Smith, R. W. Chesnut, C. Miles, S. M. Colon, and H. M. Grey. 1989. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc. Nat. Acad. Sci. USA 86:3296.
25. Rothbard, J. B., and W. R. Taylor. 1988. A sequence pattern common to T cell epitopes. EMBO J. 7:93.
26. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell 74:197.
27. Hammer, J., C. Belunis, D. Bolin, J. Papadopoulos, R. Walsky, J. Higelin, W. Danho, F. Sinigaglia, and Z. Nagy. 1994. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. USA 91:4456.
28. Hammer, J., E. Bono, F. Gallazi, C. Beunis, Z. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353.
29. Sette, A., J. Sidney, C. Oseroff, M-F. del Guercio, S. Southwood, T. Arrhenius, M. Powell, S. M. Colon, F. Gaeta, and H. M. Grey. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151:3163.
30. Marshall, K., K. J. Wilson, J. Liang, A. Woods, D. Zaller, and J. B. Rothbard. 1995. Prediction of peptide affinity to HLA DRB1*0401. J. Immunol. 154:5927.
31. Sidney, J., C. Oseroff, S. Southwood, M. Wall, R. W. Karr, G. Ishioka, F. Koning, and A. Sette. 1992. DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DRβ1 alleles. J. Immunol. 149:2643.
32. O'Sullivan, D. T., T. Arrhenius, J. Sidney, M-F. del Guercio, M. Albertson, M. Wall, S. Southwood, S. M. Colon, F. Gaeta, and A. Sette. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles: identification of common structural motifs. J. Immunol. 147:2663.
33. Hill, C. M., A. Liu, K. W. Marshall, J. Mayer, B. Jorgensen, B. Yuan, R. M. Cubbon, E. A. Nichols, L. S. Wicker, and J. B. Rothbard. 1994. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J. Immunol. 152:2890.
34. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H-G. Rammensee. 1994. Pool sequencing of natural HLA-DR, DQ, DP ligands reveals detailed peptide motifs, constraints of processing and general rules. Immunogenetics 39:230.
35. Doolan, D., A. Saul, and M. Good. 1997. Geographically restricted heterogeneity of the Plasmodium falciparum circumsporozoite protein: relevance for vaccine development. Infect. Immun. 60:675.
36. Hoffman, S. L., E. Franke, M. Hollingdale, and P. Druilhe. 1996. Attacking the infected hepatocyte. In Malaria Vaccine Development: A Multi-Immune Response Approach, S. L. Hoffman, ed. American Society for Microbiology, Washington, DC, p. 35.
37. Melief, C. J. M., R. Offringa, R. E. M. Toes, and W. M. Kast. 1996. Peptide-based cancer vaccines. Curr. Opin. Immunol. 8:651.
38. Chesnut, R. W., A. Sette, E. Celis, P. Wentworth, R. T. Kubo, J. Alexander, G. Ishioka, A. Vitiello, and H. M. Grey. 1995. Design and testing of peptide based cytotoxic T-cell mediated immunotherapeutics to treat infectious diseases and cancer. In Vaccine Design: The Subunit and Adjuvant Approach, M. F. Powell and M. J. Newman, eds. Plenum Press, New York, p. 847.
39. Miller, L. H., T. Roberts, M. Shahabuddin, and T. McCutchan. 1993. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59:1.
40. Howard, C. R., and L. M. Allison. 1995. Hepatitis B surface antigen variation and protective immunity. Intervirology 38:35.
41. Simmonds, P. 1995. Variability of hepatitis C virus. Hepatology 21:570.
42. Sillier-Moiseiwitsch, F., B. H. Margolin, and R. Swanstrom. 1994. Genetic variability of the human immunodeficiency virus: statistical and biological issues. Annu. Rev. Genet. 28:559.
43. Nardin, E. H., and R. S. Nussenzweig. 1993. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 11:687.
44. van der Most, R. G., A. Sette, C. Oseroff, J. Alexander, L. L. Lau, S. Southwood, J. Sidney, R. W. Chesnut, M. Matoubian, and R. Ahmed. 1996. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157:5543.
45. van der Most, R. G., R. J. Concepcion, C. Oseroff, J. Alexander, S. Southwood, J. Sidney, R. W. Chesnut, R. Ahmed, and A. Sette. 1997. Uncovering subdominant cytotoxic T-lymphocyte choriomeningitis virus infected BALB/c mice. J. Virol. 71:5110.
46. Vitiello, A., L. Yuan, R. W. Chesnut, J. Sidney, S. Southwood, P. Farness, M. R. Jackson, P. A. Peterson, and A. Sette. 1996. Immunodominance analysis of CTL responses to the influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J. Immunol. 157:5555.
47. Sercarz, E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.
48. Cibotti, R., J. M. Kanellopoulos, J.-P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Lourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416.
49. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796.
50. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltration T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
51. Alexander, J., J. Sidney, S. Southwood, S. Maewal, J. Ruppert, C. Oseroff, R. T. Kubo, A. Sette, and H. M. Grey. 1994. Development of high potency universal DR-restricted helper epitopes by rational engineering of high affinity DR blocking peptides. Immunity 1:751.
52. Parkhurst, M. R., M. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Efficient induction of melanoma reactive CTL with peptides modified at HLA-A *0201 binding residues from the melanoma antigen, gp100. J. Immunol. 157:2539.
53. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 186: 1965.
54. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary CTL response in man. J. Clin. Invest. 95:341.
55. Perkus, M. E., and E. Paoletti. 1996. Recombinant virus as vaccination carrier of heterologous antigens. In Concepts in Vaccine Development, S. H. E. Kaufmann, ed. Walter de Gruyter and Co., Berlin, p. 379.
56. Top, F. H., R. A. Grossman, P. J. Bartelloni, H. E. Segal, B. A. Dudding, P. K. Russell, and E. L. Buescher. 1971. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J. Infect. Dis. 124:148.
57. Kofler, N., C. Ruedl, J. Klima, H. Recheis, G. Bock, G. Wick, and H. Wolf. 1996. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L lactic acid) microspheres with entrapped pneumotropic bacterial antigens. J. Immunol. Methods 192:25.
58. Eldridge, J. H., J. K. Stass, D. Chen, P. A. Marx, T. R. Tice, and R. M. Gilley. 1993. New advances in vaccine delivery systems. Semin. Hematol. 30:16.
59. Falo, Jr., L. D., M. Kovacsovics-Bankowski, K. Thompson, and K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 7:649.
60. Warren, H. S., F. R. Vogel, and L. A. Chedid. 1986. Current status of immunological adjuvants. Annu. Rev. Immunol. 4:369.
61. Gupta, R. K., E. H. Relyveld, E. B. Lindblad, B. Bizzini, S. Ben-Efraim, and C. K. Gupta. 1993. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 11:293.
62. Reddy, R., R. Zhou, S. Nair, L. Huang, and B. T. Rouse. 1992. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1585.
63. Shiver, J. W., J. B. Ulmer, J. J. Donnelly, and M. A. Liu. 1996. Naked DNA vaccination. In Concepts in Vaccine Development, S. H. E. Kaufmann, ed. Walter de Gruyter and Co., Berlin, p. 379.
64. Bodmer, J. G., S. G. E. Marsh, E. D. Albert, W. F. Bodmer, R. E. Bontrop, D. Charron, B. Dupont, H. A. Erlich, B. Mach, W. R. Mary, P. Parham, T. Sasazuki, G. M. T. Schreuder, J. L. Strominger, A. Svejgaard, and P. I. Terasaki. 1995. Nomenclature for factors of the HLA system. Hum. Immunol. 43:149.
65. Parham, P., E. J. Adams, and K. L. Arnett. 1995. The origins of HLA-A, B, C polymorphism. Immunol. Rev. 143:141.
66. Sidney, J., H. M. Grey, S. Southwood, E. Celis, P. A. Wentworth, M-F. del Guercio, R. T. Kubo, R. W. Chesnut, and A. Sette. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide binding repertoires of common HLA molecules. Hum. Immunol. 45:79.
67. Sidney, J., H. M. Grey, R. T. Kubo, and A. Sette. 1996. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 17:261.
68. Sidney, J., M-F. del Guercio, S. Southwood, V. H. Engelhard, E. Appella, H. M. Grey, and A. Sette. 1995. Several HLA alleles share overlapping peptide specificities. J. Immunol. 154:247.
69. del Guercio, M-F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685.
70. Sidney, J., S. Southwood, M-F. del Guercio, H. M. Grey, R. W. Chesnut, R. T. Kubo, and A. Sette. 1996. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J. Immunol. 157:3480.
71. Sinigaglia, F., M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. L. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778.
72. Ferrari, C., A. Bertoletti, A. Penna, A. Cavilli, A. Valli, G. Missale, M. Pilli, P. Fowler, T. Giuberti, F. V. Chisari, and F. Fiaccadori. 1991. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin. Invest. 88:214.
73. Busch, R., G. Strang, K. Howland, and J. B. Rothbard. 1990. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int. Immunol. 2:443.
74. Roche, P. A., and P. Cresswell. 1991. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144:1849.
75. Sette, A., S. Southwood, J. Miller, and E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181:677.
76. Malcherek, G., V. Gnau, G. Jung, H.-G. Rammensee, and A. Melms. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many ajor histocompatibility complex-class II molecules. J. Exp. Med. 181:527.
77. Valli, A., A. Sette, L. Kappos, C. Oseroff, J. Sidney, G. Miescher, M. Hochbergger, E. D. Albert, and L. Adorini. 1993. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91:616.
78. Sette, A., S. Buus, S. M. Colon, C. Miles, and H. M. Grey. 1989. Structural analysis of peptides capable of binding to more than one Ia antigen. J. Immunol. 142:35.
79. Gorga, J. C., V. Horejsi, D. R. Johnson, R. Raghupathy, and J. L. Strominger. 1987. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J. Biol. Chem. 262:16087.
80. Sette, A., S. Southwood, D. O'Sullivan, F. C. A. Gaeta, J. Sidney, and H. M. Grey. 1992. Effect of pH on MHC class II-peptide interactions. J. Immunol. 148:844.
81. Buus, S., A. Sette, S. M. Colon, C. Miles, and H. M. Grey. 1987. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235:1353.
82. Boitel, B., U. Blank, D. Mege, G. Corradin, J. Sidney, A. Sette, and O. Acuto. 1995. Strong similarities in antigen fine specificity among DRB1* 1302-restricted tetanus toxin tt830-843-specific TCRs in spite of highly heterogeneous CDR3. J. Immunol. 154:3245.
83. O'Sullivan, D., J. Sidney, E. Appella, L. Walker, L. Phillips, S. M. Colon, C. Miles, R. W. Chesnut, and A. Sette. 1990. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145:1799.
84. Wucherpfennig, K. W., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. I. Strominger, and D. A. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:279.
85. Cotner, T. H., H. Charbonneau, E. Mellins, and D. Pious. 1989. mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DRβ1 and -DRβ3 molecules. J. Biol. Chem. 264:11107.
86. Gulukota, K., J. Sidney, A. Sette, and C. DeLisi. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258.
87. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
88. Marshall, K. W., A. F. Liu, J. Canales, B. Perahia, B. Jorgensen, R. D. Gantzos, B. Aguilar, B. Devaux, and J. B. Rothbard. 1994. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol. 152:4946.
89. Imanishi, T., T. Akaza, A. Kimura, K. Tokunaga, and T. Gojobori. 1991. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA Proceeding of the Eleventh International Histocompatibility Workshop and Conference, K. Tsuji, M. Aizaqa, and T. Sasazuki, eds. Oxford University Press, Tokyo, p. 1065.
90. Kinouchi, R., H. Kobayashi, K. Sato, S. Kimura, and M. Katagiri. 1994. Peptide motifs of HLA-DR4/DR53 (DRB1*0405/DRB4*0101) molecules. Immunogenetics 40:376.
91. Martin, R., M. D. Howell, D. Jaraquemada, M. Flerlage, J. Richert, S. Brostoff, E. O. Long, D. E. McFarlin, and H. F. McFarland. 1991. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173:19.
92. Sinigaglia, F., M. Guttinger, M. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. L. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778.
93. Malcherek, G., K. Falk, O. Rötzschke, H.-G. Rammensee, S. Stevanovic, V. Gnau, G. Jung, and A. Melms. 1993. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol. 5:1229.
94. Geluk, A., K. E. van Meijgaarden, S. Southwood, C. Oseroff, J. W. Drijfhout, R. R. P. de Vries, T. H. M. Ottenhoff, and A. Sette. 1994. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152: 5742.
95. D'Amaro, J., J. G. A. Houbiers, J. W. Drijfhout, R. M. P. Brandt, R. Schipper, J. N. B. Bavinck, C. J. M. Melief, and W. M. Kast. 1995. A computer program for predicting possible cytotoxic T lymphocytes epitopes based on HLA class I peptide-binding motifs. Hum. Immunol. 43:13.